Focusing on genetically defined population still couldn't save Eli Lilly, Roche's anti-amyloid Alzheimer's drugs
Neither Eli Lilly or Roche got any closer to proving their anti-amyloid therapies have a shred of value in the fight against Alzheimer’s as they …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
